The 2009 Influenza A H1N1 Antiviral Resistance test is designed to detect mutations of the pandemic Influenza strain that are resistant to oseltamivir (Tamiflu?®). CDC recently reported cases of immunocompromised patients who were carrying oseltamivir-resistant mutations of 2009 Influenza A H1N1. ViraCor-IBT ™s test will allow physicians to identify mutations of the Influenza A H1N1 virus that convey resistance to oseltamivir.

The new testing service offers physicians and laboratories several ordering options, including reflex testing, which allows ViraCor-IBT to perform a needed second test without having to re-contact the ordering physician.

ViraCor-IBT is committed to providing hospitals and physicians the most advanced testing options along with the fastest turnaround time of patient results in the industry, said John Martin, president of the combined ViraCor-IBT Laboratories. As we head into an unpredictable flu season, we are pleased to offer not only a high quality molecular H1N1 test, but three additional assays that will give our clients the tools and information they need to help diagnose and treat influenza and other respiratory illnesses and provide the best possible patient care.

All of ViraCor-IBT ™s respiratory virus testing options will be available as of September 1, 2009, with the exception of the 2009 Influenza A H1N1 Antiviral Resistance test, which will be available later in the month. To learn more about the influenza and respiratory virus testing service, please visit www.viracor-ibt.

viracor-ibt/